13th May 2022 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, today announced that an abstract on further findings of patients treated in its phase I/IIa WiNK trial have been accepted and will be presented at the European Hematology Association (EHA) 2022 Congress, which will take place 9th – 12th June 2022 in Vienna, Austria. oNKord® is the company’s first-generation off-the-shelf allogeneic NK cell therapy under clinical development. Glycostem is furthermore developing a range of CAR-NK, combination therapy and TCR-NK products in-house.
“Achieving measurable residual disease (MRD) negativity is associated with longer-term survival in patients with AML. Our initial clinical data shows that all patients in the first dose cohort reached some level of MRD negativity with an excellent safety profile thus far.” said Dr. Kai Pinkernell, CMO of Glycostem. “We are looking forward to the results on the following, increased dose levels, which we expect to further support the safety and activity of oNKord® as shown in the early follow up.”
The EHA abstract is now available at https://ehaweb.org/ as EHA-3555 with the title:
Early safety and clinical course of patients with acute myeloid leukemia and measurable residual disease receiving gta002, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation.
Glycostem will present the poster on Friday, 10th June 2022 at 16:30 – 17:45 CEST.
